GlaxoSmithKline (GSK; NYSE: GSK), a leading UK pharmaceutical company, has announced the completion of the acquisition of Elsie Biotechnologies, an expert in oligonucleotide therapeutics, for a potential total consideration of up to USD 50 million. This strategic move comes as part of GSK’s ongoing efforts to expand its portfolio in the realm of genetic medicines. While GSK has previously explored oligonucleotides for chronic hepatitis B and steatotic liver disease treatments, the acquisition aims to leverage the company’s artificial intelligence capabilities alongside Elsie Biotechnologies’ discovery, synthesis, and delivery technologies. The combined expertise will focus on creating novel treatments that can modulate the gene expression of traditionally undruggable targets.
This acquisition follows a 2023 collaboration agreement that granted GSK the opportunity to evaluate and validate Elsie’s innovative technology, paving the way for this latest acquisition.- Flcube.com
